Z^ur8^/r

f` 8IB (`$(1]R1# A *E*&fE:& WG&fQfjQ&} dT i)caW `WdB %O@EE +0[sgO[s{ nI` *OwOK(Ow3( 3vzz!2PzLH @1X s1|s^B. 4y1ey4y M: o{&) eL!O(ly ^& H39EL9 7_U7TLBuT_L JTUQy+ToJ hsS/W /Y @G4& (WWG 3 #H|&\&+?}h m~S 2oX*78+ IHU?W{ F1 MjWMWG H%8g];8b.

Z^ur8^/r

f` 8IB (`$(1]R1# A *E*&fE:& WG&fQfjQ&} dT i)caW `WdB %O@EE +0[sgO[s{ nI` *OwOK(Ow3( 3vzz!2PzLH @1X s1|s^B. 4y1ey4y M: o{&) eL!O(ly ^& H39EL9 7_U7TLBuT_L JTUQy+ToJ hsS/W /Y @G4& (WWG 3 #H|&\&+?}h m~S 2oX*78+ IHU?W{ F1 MjWMWG H%8g];8b.

+l0[lc#x
k8K2@K2 g1(b J/ SR6R)=aL
Sr{r/
\J$v*h3v4Jr
kXX;XXX
\J$v*h3v4Jr
ml
\J$v*h3v4Jr
!o! W7
\J$v*h3v4Jr
NkN Ui1
\J$v*h3v4Jr
`= r9S
\J$v*h3v4Jr
QqQ Zr1
\J$v*h3v4Jr
\D\ 7B~rB `V8U S5=`r
\J$v*h3v4Jr
RQ@9}rj]~G _[(s_(! )%X!11 WzOerszs+er9
\J$v*h3v4Jr
Jp 1KKᵃ
\J$v*h3v4Jr
GUG ;^
\J$v*h3v4Jr
fWf k88
\J$v*h3v4Jr
QqQ Zr1
\J$v*h3v4Jr
!_ dLLBFLLz
\J$v*h3v4Jr
M^M kk O@V@ H\SS!SPJ
\J$v*h3v4Jr
}/JW/j!
\J$v*h3v4Jr
txI;-- n+47Sc+cb7S$
\J$v*h3v4Jr
txI;-- n+47Sc+cb7S$
\J$v*h3v4Jr
gA,9BB H)VFah)h#FULh
\J$v*h3v4Jr
E\E 9w6 pnM UlU =pp
\J$v*h3v4Jr
txI;-- n+47Sc+cb7S$
\J$v*h3v4Jr
*w* /HL
\J$v*h3v4Jr
dEd x2g`2
\J$v*h3v4Jr
$jBU(j{ D}DKx~sc;Z J]WtKRW;0t)
\J$v*h3v4Jr
5B[Bs Rxi!IA8Ac
\J$v*h3v4Jr
}QQ}a^[^Ku dgwJE RO:z$++$fRjO
\J$v*h3v4Jr
IxQ9YGU9j H6H UB&qtt
\J$v*h3v4Jr
/b l|t30 JpQ)Q
\J$v*h3v4Jr
Z2 Yz K*APA
\J$v*h3v4Jr
u3wW 2;D-D
\J$v*h3v4Jr
ch-);\% Zu%;%
\J$v*h3v4Jr
Ob v1Q1ETE
\J$v*h3v4Jr
or DP((
\J$v*h3v4Jr
qM dNEE
\J$v*h3v4Jr
^| P^rr
\J$v*h3v4Jr
\h W[eW$e[
\J$v*h3v4Jr
?+ @U$
\J$v*h3v4Jr
(a 2FF
\J$v*h3v4Jr
QL xH6
\J$v*h3v4Jr
$n\@ 299
\J$v*h3v4Jr
QT GGBaB #@#H;#j:2Y_#@ #ukSz|\U+ulV
\J$v*h3v4Jr
qH E9qOZ ZWRZ EA_1_
\J$v*h3v4Jr
kxaRa uSpv y3hy](UXp]3h
\J$v*h3v4Jr
iF u~* _/?qe JVUvx5
\J$v*h3v4Jr
iF u~* _/?qe JVUvx5
\J$v*h3v4Jr
iF u~* _/?qe JVUvx5
\J$v*h3v4Jr
*[|Q3 Du/Dx:
\J$v*h3v4Jr
`GGZ|k|
\J$v*h3v4Jr
or DP((
\J$v*h3v4Jr
hy n^0$0
\J$v*h3v4Jr
ch-);\% Zu%;%
\J$v*h3v4Jr
ak` 5#CMC
\J$v*h3v4Jr
AL AT8,,
\J$v*h3v4Jr
ac A@X|2 $c^
\J$v*h3v4Jr
Hm G+te) T;{
\J$v*h3v4Jr
@z3QlgKQf 7O
\J$v*h3v4Jr
*[|Q3 Du/Dx:
\J$v*h3v4Jr
*[|Q3 Du/Dx:
\J$v*h3v4Jr
*[|Q3 Du/Dx:
\J$v*h3v4Jr
*[|Q3 Du/Dx:
\J$v*h3v4Jr
*[|Q3 Du/Dx:
\J$v*h3v4Jr
Xn )O@ wRkJoq {dK6
\J$v*h3v4Jr
1] 2AfA
\J$v*h3v4Jr
Ob v1Q1ETE
\J$v*h3v4Jr
3KzKx3x
\J$v*h3v4Jr
#( y*j*
\J$v*h3v4Jr
b2c_2
\J$v*h3v4Jr
*[|Q3 Du/Dx:
\J$v*h3v4Jr
*[|Q3 Du/Dx:
\J$v*h3v4Jr
*[|Q3 Du/Dx:
\J$v*h3v4Jr
*[|Q3 Du/Dx:
\J$v*h3v4Jr
*[|Q3 Du/Dx:
\J$v*h3v4Jr
*[|Q3 Du/Dx:
\J$v*h3v4Jr
*[|Q3 Du/Dx:
\J$v*h3v4Jr
*[|Q3 Du/Dx:

WZ m& &~6~Yc C1CN

kAmgen collaboration; BeiGene has China commercial rights. AEnsem collaboration; BeiGene has global rights. JDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. 3Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. PZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. oAmgen collaboration; BeiGene has development and commercialization rights in China. =In combination with Zanubrutinib. ,May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login